Sarepta Therapeutics shares rise 1.33% premarket after multiple lawsuits filed against the company.

Sarepta Therapeutics, Inc. rose 1.33% in premarket trading. The company is facing multiple class action lawsuits, with Kessler Topaz Meltzer & Check, LLP and Pomerantz LLP filing lawsuits against Sarepta on behalf of investors who purchased or otherwise acquired Sarepta securities between June 22, 2023, and June 24, 2025. The lawsuits allege that Sarepta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.